SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
Item 7.01 Other Events

Story continues below

On April 11, 2019, Second Sight Medical Products, Inc. (the “Company”) issued a press release announcing that Dr. Jessy D. Dorn, Ph.D., Sr. Director of Scientific Research, will present an update on the Early Feasibility Study of the Orion® Visual Cortical Prosthesis System at the Fifth Annual BRAIN Initiative® Investigators Meeting to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 11, 2019.

A copy of the Company’s press release entitled “Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative Investigators Meeting” is furnished as Exhibit99.1 to this Current Report on Form8-K.

Item 7.01.REGULATION FD DISCLOSURE

Second Sight Medical Products, Inc. (the “Company”) intends to present a poster entitled “Early Feasibility Study of a Visual Cortical Prosthesis for the Blind: The Orion Visual Prosthesis System” (the “Poster”) at the Fifth Annual BRAIN Initiative® Investigators Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. on April 11, 2019, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.2 and incorporated herein by reference.

A copy of a slide presentation that the Company intends to use in a presentation by Dr. Jessy D. Dorn, Ph.D., Sr. Director of Scientific Research, also to be made at the Fifth Annual BRAIN Initiative® Investigators Meeting (the “Presentation Materials”), is attached to this Current Report on Form 8-K as Exhibit 99.3, and is incorporated herein by reference.

The Poster and the Presentation Materials provide an update on the Early Feasibility Study of the Orion® Visual Cortical Prosthesis System. The Poster and the Presentation Materials contain information as of the date of this Current Report on Form 8-K, or otherwise noted in the materials.WhileSecond Sightmay elect to update the Poster or the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K,Second Sight specifically disclaims any obligation to do so.

The information contained in this Item 7.01, Exhibit 99.2, and Exhibit 99.3 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 7.01 FINANCIAL STATEMENTS AND EXHIBITS

SECOND SIGHT MEDICAL PRODUCTS INC Exhibit
EX-99.1 2 eyes-ex991_82.htm EX-99.1 eyes-ex991_82.htm Exhibit 99.1 FOR IMMEDIATE RELEASE   Second Sight Medical Products,…
To view the full exhibit click here

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

An ad to help with our costs